BCL2 and neoplasm: Studies have shown that tumor-derived exosomal miR-21 and miR-522-3p could participate in gefitinib resistance by regulating PI3K/Akt signaling pathway, while exosomal miR-214 could confer gefitinib resistance via Bax/Bcl2 signaling (73–75).